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Youth with attention deficit hyperactivity disorder (ADHD) have deficits in interference inhibition, which can be improved with the
indirect catecholamine agonist methylphenidate (MPH). Functional magnetic resonance imaging was used to investigate the effects of a
single dose of MPH on brain activation during interference inhibition in medication-naı ¨ve ADHD boys. Medication-naı ¨ve boys with
ADHD were scanned twice, in a randomized, double-blind design, under either a single clinical dose of MPH or placebo, while
performing a Simon task that measures interference inhibition and controls for the oddball effect of low-frequency appearance of
incongruent trials. Brain activation was compared within patients under either drug condition. To test for potential normalization effects
of MPH, brain activation in ADHD patients under either drug condition was compared with that of healthy age-matched comparison
boys. During incongruent trials compared with congruent–oddball trials, boys with ADHD under placebo relative to controls showed
reduced brain activation in typical areas of interference inhibition, including right inferior prefrontal cortex, left striatum and thalamus,
mid-cingulate/supplementary motor area, and left superior temporal lobe. MPH relative to placebo upregulated brain activation in right
inferior prefrontal and premotor cortices. Under the MPH condition, patients relative to controls no longer showed the reduced
activation in right inferior prefrontal and striato-thalamic regions. Effect size comparison, furthermore, showed that these normalization
effects were significant. MPH significantly normalized the fronto-striatal underfunctioning in ADHD patients relative to controls during
interference inhibition, but did not affect medial frontal or temporal dysfunction. MPH therefore appears to have a region-specific
upregulation effect on fronto-striatal activation.
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INTRODUCTION
Childhood attention deficit hyperactivity disorder (ADHD)
is defined by age-inappropriate inattention, impulsiveness,
and hyperactivity (DSM IV) (American Psychiatric Associa-
tion, 1994). ADHD has consistently been associated with
neuropsychological deficits in tasks of motor and inter-
ference inhibition (Rubia et al, 2010a, 2011; Willcutt et al,
2005). This has been underpinned by neuroimaging
evidence for reduced activation of inhibition-associated
inferior prefrontal and caudate regions (Konrad et al, 2006;
Rubia et al, 1999, 2005, 2008, 2010a), as well as more generic
regions of cognitive control and attention in cingulate
and parieto-temporal cortices during these and related tasks
(Rubia et al, 1999, 2005, 2008, 2010a, 2011; Vaidya et al,
2005). Psychostimulants, including methylphenidate (MPH)
and amphetamines, are the most effective, first-choice
treatment for ADHD, improving symptoms in 70% of
patients (Arnsten, 2006a; Wilens, 2008). MPH is a
catecholamine reuptake inhibitor with stronger dopamine
(DA) upregulating effects in striatal regions and both
DA and noradrenaline upregulating effects in cortical
areas (Arnsten, 2006a). There is consistent evidence that
the behavioral and cognitive features of ADHD are
mediated, at least in part, by catecholamine dysfunction,
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DA transporter (DAT) levels and reduced DA availability
in the basal ganglia (Krause, 2008; Volkow et al, 2006,
2007a,b). Relatively little, however, is known on the effects
of MPH on brain function in ADHD. MPH has been shown
to improve performance on motor and interference inhibi-
tion tasks (DeVito et al, 2009; Langleben et al, 2006;
Tannock et al, 1989). Relatively few functional magnetic
resonance imaging (fMRI) studies, however, have investi-
gated the acute effects of MPH on neural networks of
inhibition functions. Vaidya et al (1998) found that the
single dose of MPH upregulated defined regions of interest
of caudate, anterior cingulate, and frontal brain regions in
previously medicated children with ADHD during motor
response inhibition. A recent study found no effect of a
single dose MPH administration on the neural networks of
interference inhibition in medication-responsive patients
with ADHD, but on anterior and posterior cingulate
activation during the control condition, which was inter-
preted as enhancement of the default-mode network
suppression (Peterson et al, 2009). A study in adults with
ADHD testing for 6 weeks of chronic effects of MPH on
brain activation during a multi-source interference inhibi-
tion task found an enhancement effect on anterior cingulate
as well as dorsolateral prefrontal, striato-thalamic, and
parietal activation (Bush et al, 2008). All these studies were
conducted in previously medicated patients with ADHD.
Longitudinal studies, however, suggest that long-term
medication may have an effect on both brain structure
(Shaw et al, 2009) and function (Konrad et al, 2007).
To overcome these limitations, we aimed to investigate
the effect of MPH on neural processes of interference
inhibition in medication-naı ¨ve boys with ADHD. Imaging
studies of interference inhibition tasks are typically
confounded by the mismatch in frequency between low
frequent interference inhibition and high frequent con-
gruent trials, co-measuring the attentional oddball effect to
less frequent trials. To avoid this confound, we used our
fMRI paradigm of the Simon task that incorporates an
oddball task to control for the attention allocation effect
(Rubia et al, 2011; Smith et al, 2006). In healthy adolescents,
task performance activates bilateral dorsolateral and inferior
prefrontal, basal ganglia, thalamus, anterior cingulate, and
temporal brain regions (Christakou et al,2 0 0 9 a ;R u b i aet al,
2006). Children with ADHD relative to controls have shown
reduced activation in fronto-striatal, medial frontal/anterior
cingulate, and temporo-parietal regions during this (Rubia
et al, 2009c, 2011) and similar interference inhibition tasks
(Konrad et al, 2006; Vaidya et al, 2005).
We hence conducted a randomized, double-blind, place-
bo-controlled pharmacological fMRI experiment to test for
the effects of a single acute clinical dose of MPH on brain
activation in 12 medication-naı ¨ve boys with ADHD during
interference inhibition. Furthermore, brain activation in
ADHD patients at baseline and after MPH was compared
with that of a healthy age-matched control group, to test for
potential amelioration or normalization effects of MPH on
brain dysfunctions during the placebo condition. During
tasks of sustained attention and time estimation, we
previously observed normalization of fronto-striatal and
parietal brain activation in medication-naı ¨ve patients with
ADHD (Rubia et al, 2009a,b). We therefore hypothesized
that during interference inhibition, MPH would upregulate
and normalize areas of underactivation that are typically
observed in ADHD patients relative to controls during this
task in inferior and medial frontal/anterior cingulate and
striatal brain regions.
METHODS
Subjects
Twelve male medication-naı ¨ve, right-handed boys aged
10–15 years who met clinical diagnostic criteria for the
combined (inattentive–hyperactive) subtype of ADHD
(DSM-IV), with a mean age of 13 years (SD¼1), were
recruited through clinics. One additional patient was
recruited but not included in the study owing to movement
artifacts and non-completion of the second scan. Clinical
diagnosis of ADHD was established through interviews
with an experienced child psychiatrist (A-MM) using the
standardized Maudsley diagnostic interview to check
the presence or absence of each of the criteria and applying
the numerical cutoffs for numbers of symptoms in each
domain as set out by DSM-IV (Goldberg and Murray, 2002).
The Maudsley diagnostic interview contains items on
symptoms of ADHD, autism, conduct, bipolar, affective
and anxiety, and other pervasive developmental disorders.
Items were then combined into diagnoses following the
rules of the ICD-10 (Research Diagnostic Criteria), except
that for ADHD the criteria of the DSM-IV (TR) were
followed. Exclusion criteria were lifetime co-morbidity with
any other psychiatric disorder, except for conduct/opposi-
tional defiant disorder (present in one patient), as well as
learning disability and specific reading disorder (as assessed
by the full developmental and educational history of the
child, taken from parent/carer, by school information, and
by excluding subjects with a Raven’s IQ lower than the 5th
percentile), neurological abnormalities, epilepsy, drug or
substance abuse, and previous exposure to stimulant
medication. Patients with ADHD had to also score above
cutoff for hyperactive–inattentive symptoms on the
Strengths and Difficulties Questionnaire (SDQ) for parents
(Goodman and Scott, 1999). Patients were scanned twice, in
a randomized, counter-balanced manner, 1 week apart, 1h
after either 0.3mg/kg of MPH administration or placebo
(vitamin C, 100mg).
Thirteen male right-handed boys in the age range of 11–
16 years (mean age¼13, SD¼1) were recruited through
advertisements in the same geographic areas of South
London to ensure similar socioeconomic status. They
scored below the cutoff for behavioral problems in the
SDQ, and had no history of psychiatric disorder.
All participants were above the 5th percentile on the
Raven progressive matrices performance IQ (Raven, 1960)
(IQ mean estimate: controls¼102, SD¼15; ADHD¼90,
SD¼9) and paid d30 for participation. Parental and child
informed consent/assent and approval from the local
Ethical Committee was obtained.
Univariate ANOVAs showed no group differences between
boys with ADHD and controls for age (F (1.25)¼1.7, p¼0.2),
but there was a significant difference in IQ (F (1.25)¼5.5,
po0.023). Consequently, all between-group performance and
imaging data analyses were covaried for IQ.
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Subjects practiced the Simon task once before scanning.
The 6min fMRI adaptation of the Simon task involves a
stimulus–response incompatibility effect and measures
interference inhibition and selective attention. To control
for the attentional oddball effect of low-frequency
appearance of incongruent trials, the task contains an
oddball condition (Rubia et al, 2006, 2009c, 2011; Smith
et al, 2006).
Subjects have to press a left/right button depending on
whether an arrow stimulus of 300ms duration points either
to the left or right side of the screen. The mean ITI was 1.8s,
but jittered between 1.6 and 2s for optimal statistical
efficiency of fast event-related fMRI data analysis (Dale,
1999). In congruent trials (160 trials), the arrow pointing
left (right) appears on the left (right) side of the screen. In
12% of trials (24 trials), arrows appear on the opposite side
of where they point and subjects have to inhibit responding
according to the interfering, predominant spatial informa-
tion while continuing to respond to the iconic information
(arrow direction). To control for the attentional oddball
effect of the low-frequency appearance of the incongruent
trials, slightly slanted ‘oddball’, but congruent stimuli
appeared in another 12% of trials (24 trials), to which
subjects have to respond to as to the congruent stimuli.
The event-related analysis compares successfully per-
formed incongruent with successfully performed oddball
trials to measure the neural correlates of interference
inhibition, controlling for the attentional oddball effect
(incongruent–oddball trials).
fMRI Image Acquisition
Gradient-echo echoplanar MRI data were acquired on a
GE Signa 1.5T Horizon LX System (General; Electric,
Milwaukee, WI) at the Maudsley Hospital (London, UK).
A quadrature birdcage head coil was used for RF transmis-
sion and reception. In each of the 16 non-contiguous planes
parallel to the anterior–posterior commissural, 208
T2 *-weighted MR images depicting BOLD (Blood Oxygen
Level Dependent) contrast covering the whole brain were
acquired with TE¼40ms, TR¼1.8s, flip angle¼901, in-
plane resolution¼3.1mm, slice thickness¼7mm, and slice
skip¼0.7mm, providing complete brain coverage.
fMRI Image Analysis
The method of fMRI analysis used (XBAM, http://
www.brainmap.co.uk) (Brammer et al, 1997) makes no
normality assumptions, which are usually violated in fMRI
data, but instead uses median statistics to control outlier
effects and permutation, rather than normal theory-based
inference. Furthermore, the most common test statistic is
computed by standardizing for individual difference in
residual noise before embarking on second-level, multi-
subject testing using robust permutation-based methods.
This allows a mixed-effects approach to analysisFan
approach that has recently been recommended following a
detailed analysis of the validity and impact of normal
theory-based inference in fMRI in large number of subjects
(Thirion et al, 2007).
Individual Analyses
fMRI data were realigned to minimize motion-related
artifacts (Bullmore et al, 1999) and smoothed using a
Gaussian filter (full-width half-maximum, 7.2mm). Time-
series analysis of individual subject activation was per-
formed using XBAM, with a wavelet-based re-sampling
method described previously (Bullmore et al, 2001). Briefly,
we first convolved each experimental condition with two
Poisson model functions (delays of 4 and 8s). Only correct
trials were included in the analyses (ie correct incongruent/
Simon and correct oddball trials, both contrasted with
an implicit baseline, that is, congruent trials). We then
calculated the weighted sum of these two convolutions
that gave the best fit (least squares) to the time series at
each voxel.
A goodness-of-fit statistic (the SSQ-ratio) was then
computed at each voxel consisting of the ratio of the sum
of squares of deviations from the mean intensity value due
to the model (fitted time series) divided by the sum of
squares due to the residuals (original time series minus
model time series). The appropriate null distribution for
assessing significance of any given SSQ-ratio was estab-
lished using the wavelet-based data re-sampling method
(Bullmore et al, 2001) and applying the model-fitting
process to the re-sampled data. This process was repeated
20 times at each voxel and the data combined over all
voxels, resulting in 20 null parametric maps of SSQ-ratio for
each subject, which were combined to give the overall null
distribution of SSQ-ratio. The same permutation strategy
was applied at each voxel to preserve spatial correlation
structure in the data. Activated voxels, at a o1 level of type
I error, were identified through the appropriate critical
value of the SSQ-ratio from the null distribution. Individual
SSQ-ratio maps were then transformed into standard space,
first by rigid body transformation of the fMRI data into a
high-resolution inversion recovery image of the same
subject, and then by affine transformation onto a Talairach
template (Talairach and Tournoux, 1988).
Group Analyses
A group activation map was then produced for the
experimental condition of incongruent–oddball trials by
calculating the median observed SSQ-ratio over all subjects
at each voxel in standard space and testing them against the
null distribution of median SSQ-ratios computed from the
identically transformed wavelet re-sampled data (Brammer
et al, 1997). The voxel-level threshold was first set to 0.05 to
give maximum sensitivity and to avoid type II errors. Next,
a cluster-level threshold was computed for the resulting
three-dimensional voxel clusters such that the final
expected number of type I error clusters was o1 per whole
brain. The necessary combination of voxel and cluster-level
thresholds was not assumed from theory, but rather was
determined by direct permutation for each data set, giving
excellent type II error control (Bullmore et al, 1999). Cluster
mass rather than a cluster extent threshold was used, to
minimize discrimination against possible small, strongly
responding foci of activation (Bullmore et al, 1999). For the
group activation analyses, less than one false-positive
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po0.05 at cluster level.
Within- and Between-Group Comparisons
For the within-group comparisons of the effect of MPH vs
placebo on brain activation, one-way repeated measures
ANOVA analyses were conducted using randomization-
based tests for voxel- or cluster-wise differences as des-
cribed in detail (Brammer et al, 1997; Bullmore et al, 2001).
This was done for the contrast condition Simon-oddball.
Less than one false-activated cluster was expected at po0.05
for voxel comparison and po0.01 for cluster comparison
for these tests.
To test for hypothesized amelioration/normalization
effects of MPH on brain activation compared with healthy
controls, two ANCOVAs with IQ estimate as covariate
were conducted: (1) between controls and boys with ADHD
under the placebo condition and (2) between controls and
boys with ADHD under the MPH condition. Less than one
false-activated cluster was expected at po0.05 for voxel
comparison and po0.01 for cluster comparison.
RESULTS
Performance Data
Within-patient comparison between MPH and placebo.
Repeated measures ANOVAs within ADHD patients showed
no significant difference between placebo or medication on
overall reaction times (RTs) (d.f.¼1,11; F¼1, po0.3),
overall error rates (d.f.¼1.11; F¼0.001, po0.9), or on the
difference in RT between incongruent and congruent trials
(Simon RT effect) (d.f.¼1.11; F¼0.05, po0.8) or the
Simon accuracy effect (differences in accuracy between
incongruent and congruent trials) (d.f.¼1.11; F¼0.2,
po0.7) (see Table 1).
Comparison between ADHD patients under placebo
compared with controls. Univariate ANCOVAs showed
that ADHD patients under placebo were slower than
controls in RTs (d.f.¼1.24; F¼7, po0.017), but did not
differ in errors (d.f.¼1.24; F¼0.8, po0.4). Repeated
measures ANCOVA for the Simon RT time and Simon
accuracy effect showed that there was no overall Simon
effect for RTs (d.f.¼1.22; F¼0.6, p¼0.4) and a trend-level
significance for a Simon accuracy effect, which was due to
larger error numbers in the incongruent compared to
congruent trials (d.f.¼1.22; F¼2, po0.1). However, no
significant interaction was observed between group and
Simon RT effect (d.f.¼1.22; F¼0.2, p¼0.7) or between
group and Simon accuracy effect (d.f.¼1.22; F¼2, p¼0.2)
(see Table 1).
Comparison between ADHD patients under MPH com-
pared with controls. Univariate ANCOVAs showed that
ADHD patients under MPH were still slower than controls
in RT (d.f.¼1.24; F¼5, po0.035), but did not differ in
errors (d.f.¼1.24; F¼1, po0.2). Repeated measures
ANOVA for the Simon RT and Simon accuracy effect
showed that there was no overall Simon effect for RT
(d.f.¼1.22; F¼0.8, p¼0.4), but a significant Simon
accuracy effect, due to larger error numbers in the
incongruent compared to congruent trials (F¼2,
po0.042). However, no significant interaction was observed
between group and Simon RT effect (RT: d.f.¼1.22; F¼0.4,
p¼0.5) or between group and Simon accuracy effect (RT:
d.f.¼1.22; F¼2, p¼0.2).
Brain Activation
Movement. There were no significant differences in the
extent of three-dimensional motion parameters between
controls and ADHD boys under placebo for x, y, z rotation
(d.f.¼3.21; F¼2, po0.14) or x, y, z translation (d.f.¼3.21;
F¼1.3, po0.3) nor between controls and ADHD boys
under MPH in x, y, z rotation (d.f.¼3.21; F¼1.7, po0.2) or
x, y, z translation (d.f.¼3,21; F¼2, po0.15). Nor were
there any differences in motion parameters for the drug
comparison within patients for x, y, z rotation (d.f.¼3,20;
F¼0.3, po0.8.) or x, y, z translation (d.f.¼3,20; F¼1,
po0.4).
One subject was excluded owing to high head movement
of over 2mm in the x, y, and z rotation and translation (see
Methods).
Within-group brain activations. Controls activated rela-
tively large clusters in right inferior prefrontal cortex,
reaching deep into insula, basal ganglia, and thalamus, in
left insula, basal ganglia, and thalamus, in left and right
dorsolateral prefrontal cortex, medial frontal cortex, in-
cluding anterior cingulate and supplementary motor area
(SMA), in left and right inferior parietal lobes and in right
superior temporal lobe.
Activation in ADHD patients under placebo was in right
inferior prefrontal cortex, reaching into insula, caudate and
putamen, in left inferior prefrontal gyrus, in ventromedial
frontal cortex, including anterior cingulate and SMA, in
thalamus, bilateral inferior parietal lobe, and in left middle
temporal gyrus.
Table 1 Main Variables of the Simon Task by Group
Performance measure Healthy controls, N¼13 ADHD placebo, N¼12 ADHD MPH, N¼12
MRT congruent (ms) 430 (72) 541 (124) 504 (124)
MRT incongruent (ms) 537 (89) 620 (122) 579 (128)
Error rate congruent (%) 2 (2) 3 (2) 2 (3)
Error rate incongruent (%) 23 (14) 19 (9) 19 (15)
Abbreviation: MRT, mean reaction time.
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inferior prefrontal cortex, reaching into insula, caudate and
putamen, and in medial frontal cortex, including anterior
cingulate and SMA (see Supplementary Figure 1).
ANOVA within-patient comparisons in brain activation
between the placebo and the MPH conditions. MPH
contrasted with placebo elicited enhanced activation in two
large clusters: one comprised right inferior prefrontal and
premotor cortex reaching into superior temporal and
inferior parietal lobes, and the other cluster comprised
left cerebellum and middle and inferior temporal lobes
(see Table 2, Figure 1). The placebo condition elicited no
enhanced activation over MPH.
Comparison between controls and ADHD patients under
either placebo or MPH. Relative to controls, ADHD
patients under the placebo condition showed underactiva-
tion in right inferior prefrontal cortex reaching into inferior
parietal lobe, in left ventromedial frontal cortex, the basal
ganglia, and thalamus, in a large cluster comprising right
SMA, anterior and posterior cingulate gyri, and in left
superior and middle temporal/occipital cortex (Table 3,
Figure 2).
Under the MPH condition, ADHD patients showed
reduced activation in the same clusters, with exception of
two previous difference clusters of activation, the one in the
left ventromedial frontal cortex, basal ganglia, and thala-
mus, and the other one in right inferior prefrontal cortex.
Between-group differences in these two clusters were no
longer observed (Figure 2, Table 3).
To establish whether the group differences between
control boys and ADHD boys under the two drug
comparisons in the inferior frontal and basal ganglia
clusters were significantly different, we directly compared
the effect sizes of the group differences in activation
resulting from the two comparisons (controls compared
with ADHD under placebo, and controls compared with
ADHD under MPH) (Matthews and Altman, 1996). When
comparing two effect sizes, the z-test can evaluate the
likelihood of whether they are significantly different. The
difference between the two effect sizes (es) can be
considered a normalized variable, where the standard error
of the difference (se) is a combination of the standard errors
of the two comparisons. Based on this, the probability
of a type I error can be calculated using the following
formula: p(a)¼(es1 es2)/sqrt(se1
2+se 2
2) (Matthews and
Altman, 1996).
The effect size comparison showed that effect sizes for the
group differences in the inferior prefrontal activation
cluster for the two comparisons were significantly different
(Statistical power of BOLD response: control, 0.0142; ADHD
placebo,  0.0153; ADHD MPH, 0.087; z¼ 1.6; po0.05) as
were the effect sizes for the group differences for the two
comparisons in the basal ganglia activation cluster (Statis-
tical power of BOLD response: control, 0.0042; ADHD
placebo,  0.0236; ADHD MPH, 0.024; z¼0.5; po0.04).
Given that the brain activation differences were based on
the higher-level contrast between Simon and Oddball
conditions, we elucidated further these activation differ-
ences by extracting BOLD responses in these between-group
difference clusters for the contrast of Simon–Oddball
condition as well as for the lower-level contrasts of
Simon–Congruent and Oddball–Congruent trials in both
groups. As can be observed in Figure 3a for the ANCOVA
difference clusters for the comparison between control boys
and ADHD boys under placebo, the group differences in all
clusters were arisen because control boys recruited these
brain regions to a greater extent for the Simon–Congruent
condition than for the Oddball–Congruent condition,
whereas in patients with ADHD, these brain regions were
more activated in the Oddball–Congruent condition than in
the Simon–Congruent condition. In other words, in healthy
boys these brain regions shifted towards greater activation
from the Oddball to the Simon condition, whereas in ADHD
patients, these brain regions showed a greater response
during the Oddball condition than the Simon condition.
For the comparison between control boys and ADHD
patients under MPH, the same patterns were observed for
the three brain clusters that remained different between
groups. In all three activation clusters, brain activation for
the Simon–Congruent condition was higher in controls than
for Oddball–Congruent condition, whereas ADHD patients
showed a more pronounced activation in these regions
during the Oddball–Congruent condition than for the
Simon–Congruent condition (see Figure 3b).
In addition, we wanted to test whether the intensity of the
brain underactivation in ADHD patients relative to controls
during the placebo condition was associated with symptom
severity. For this purpose, statistical measures of BOLD
response for each ADHD participant was extracted in
each of the significant clusters of between-group activa-
tion differences during the placebo condition and then
Table 2 Within-Group ANOVA Differences in Brain Activation in Boys with ADHD between Placebo and Methylphenidate for the Simon
Task
Brain region BA Tal. coordinates (x; y; z) No. of voxels Cluster p-value
Methylphenidate4placebo
L cerebellum/fusiform/middle/inferior temporal 37/21/19  11;  52;  13 163 0.001
R inferior frontal/premotor/superior temporal/inferior parietal 45/44/6/42/22 65;  15; 4 71 0.000
Placebo4methylphenidate
No effect
Abbreviation: BA, Brodman area.
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SDQ. We observed a negative correlation within the ADHD
group between the activation in the cluster in the basal
ganglia and inattentive–hyperactive symptoms on the SDQ
(r¼ 0.7; po0.016, two-tailed); no other correlations were
observed.
DISCUSSION
ADHD patients did not significantly differ from controls
in task performance. MPH relative to placebo had no
significant ameliorating effect on task performance within
patients or on the differences relative to healthy controls.
Figure 1 Increased brain activation with the single dose of methylphenidate compared with placebo in boys with attention deficit hyperactivity disorder
(ADHD) during interference inhibition. Axial slices for within-group analysis of variance (ANOVA) results comparing methylphenidate and placebo for the
contrast of incongruent–oddball trials at family-wise error-corrected cluster-level contrast of po0.01. Methylphenidate compared with placebo enhanced
activation in right inferior/premotor cortex and in a cluster comprising left cerebellum and middle and inferior temporal lobes. No brain regions were
enhanced under placebo compared with methylphenidate. Talairach z-coordinates are indicated for slice distance (in mm) from the intercommissural line.
The right side of the figure corresponds to the right side of the brain. The color bars indicate p-values with lighter colors reflecting more significant p-values.
Table 3 Between-Group ANCOVA Differences in Brain Activation between Control Boys and Boys with ADHD Under Either the
Placebo or the Methylphenidate Condition for the Contrast of Simon vs Oddball Condition
Brain region BA Tal. coordinates (x; y; z) No. of voxels Cluster p-value
Controls4ADHD under placebo
R inferior frontal/inferior parietal
a 45/9/40 18;  33; 59 182 0.007
L ventromedial frontal/basal ganglia/thalamus
a  25; 0; 9 242 0.003
R SMA/anterior/posterior cingulate/superior parietal 6/24/7 4;  11; 37 282 0.004
L superior/middle temporal/occipital 22/39  43;  37; 20 69 0.003
Controls4ADHD under methylphenidate
L SMA/anterior cingulate/precuneus 24/32/6/7  22;  11; 48 297 0.006
L middle temporal/occipital 19/37  36;  67;  13 53 0.001
L superior temporal/inferior parietal/precuneus 22/40/7  36;  30; 20 49 0.007
Abbreviations: BA, Brodman area; L, left; N voxels, number of voxels; R, right; SMA, supplementary motor area; Tal. coordinates, Talairach coordinates.
P-value for ANCOVAs at family-wise error-corrected cluster-level contrast of po 0.01. Boys with ADHD under placebo had no increased activation compared with
controls for either condition.
aNo differences were observed between boys with ADHD under methylphenidate and healthy control boys in these two clusters.
Figure 2 (a) Axial slices showing significantly reduced activation in boys with attention deficit hyperactivity disorder (ADHD) under placebo compared
with healthy comparison boys at family-wise error-corrected cluster-level contrast (analysis of covariance (ANCOVA)) of po0.01 for the contrast of
incongruent–oddball trials in the Simon task. No increased activation was observed in ADHD patients compared with healthy controls. (b) Under the
methylphenidate condition, brain activation differences between groups were no longer observed in the clusters in right inferior/dorsolateral prefrontal
cortex (DLPFC) and the left caudate/thalamus/ventromedial frontal lobe. Talairach z-coordinates are indicated for slice distance (in mm) from the
intercommissural line. The right side of the figure corresponds to the right side of the brain. The color bars indicate p-values with lighter colors reflecting
more significant p-values.
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upregulation and normalization effects on brain activation.
MPH elicited enhanced activation within ADHD patients in
right inferior prefrontal and premotor cortices as well as in
left cerebellum and inferior and middle temporal lobes.
When patients under placebo were compared with controls,
they showed reduced activation in right inferior prefrontal
cortex reaching into inferior parietal lobe, in left basal
ganglia and thalamus, in ventromedial and dorsomedial
prefrontal, and in temporal regions. The underactivation in
basal ganglia, thalamus, and ventromedial frontal lobe,
furthermore, was negatively associated with symptom
severity. No brain regions were increased in activation in
patients relative to controls. All activation deficit clusters
relative to controls remained when patients were under
MPH, with the exception of the underactivation clusters in
right inferior prefrontal cortex, and the symptom-severity-
associated cluster in left basal ganglia/thalamus and
ventromedial prefrontal cortex. Furthermore, the region-
specific normalization effects were significant, given that
the effect sizes of the activation differences in these two
activation clusters were significantly larger for the compa-
rison between controls and ADHD under placebo than for
the comparison between controls and ADHD under MPH.
The findings suggest that a single clinical dose of MPH has
region-specific normalization effects on abnormal brain
activation in ADHD patients in inferior and ventromedial
fronto-striatal networks during interference inhibition.
Right inferior prefrontal cortex as well as the caudate and
thalamus form part of a fronto-striatal network of motor
and interference inhibition in adults and children (Aron
and Poldrack, 2006; Li et al, 2008; Christakou et al, 2009a;
Figure 3 Standardized BOLD (Blood Oxygen Level Dependent) responses in areas of analysis of covariance (ANCOVA) group differences for (a) comparison
between healthy control boys and attention deficit hyperactivity disorder (ADHD) boys under the placebo condition and (b) comparison between healthy control
boys and ADHD boys under the methylphenidate condition. The color bars indicate p-values with lighter colors reflecting higher p-values.
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underactivation in these brain regions for ADHD patients
was specific to the interference condition, as the group
differences in these regions seemed to arise from the fact
that control boys showed more activation in these areas for
the Simon condition, whereas ADHD patients showed more
activation in these regions during the Oddball condition.
Inferior prefrontal underactivation in the context of tasks of
cognitive control is one of the most consistent findings in
fMRI studies in patients with ADHD (Dickstein et al, 2006;
Durston et al, 2003; Konrad et al, 2006; Rubia et al, 1999,
2005; Vaidya et al, 1998, 2005; for a review see Rubia
(2011)). Inferior prefrontal cortex, as well as caudate and
thalamus, have, furthermore, been found to be dysfunc-
tional in ADHD children during other, more generic
attention functions such as performance monitoring
(Pliszka et al, 2006; Rubia et al, 2010a), selective, sustained,
and flexible attention tasks (Rubia et al, 2007b, 2009b,c,d,
2010a,2011; Smith et al, 2006). Inferior prefrontal dysfunc-
tion, furthermore, appears to be a disorder-specific
neurofunctional deficit compared to patients with conduct
(Rubia et al, 2008, 2009c,d, 2010b) and obsessive-compul-
sive disorder (Rubia et al, 2010a), whereas striatal under-
activation appears to be disorder specific relative to OCD
patients (Rubia et al, 2010a,2011; for a review see Rubia
(2010)). In these data, furthermore, the activation in the
basal ganglia cluster correlated with symptom severity, so
that the ADHD patients with more severe inattention and
hyperactivity symptoms had more reduced activation. MPH
therefore appears to modulate an important neuro-func-
tional biomarker of ADHD, a dysfunction in fronto-striatal
neural networks that mediate cognitive control.
The findings of upregulation of activation in inferior
prefrontal cortex and the basal ganglia under a single dose
of MPH extend previous findings of upregulation of these
brain regions in the context of other tasks. Thus, lateral
prefrontal and caudate activation has previously been
shown to be upregulated, but not normalized in ADHD
patients with a single clinical dose of MPH during tasks of
motor response inhibition (Vaidya et al, 1998). Further-
more, our findings of a significant specific normalization
effect on the activation in left basal ganglia, but not in
temporal lobes, is in line with the study of Shafritz et al
(2004), who also found a region-specific upregulation and
normalization effect of MPH on left striatal underactivation,
but not on the underactivation of middle temporal lobe. The
finding of upregulation and normalization of right inferior
prefrontal/premotor cortex with MPH is in line with
strikingly similar findings of upregulation and normal-
ization of underfunctioning relative to controls in this
region in the same subjects with the same clinical dose of
MPH during a sustained attention task (Rubia et al, 2009b).
The upregulation effects in right prefrontal, premotor, and
left thalamic brain regions under a single dose of MPH is
also in line with evidence for longer-term, chronic
upregulation effects. Chronic doses of MPH over 6 weeks
lead to a significant upregulation of these areas in adults
with ADHD during a different interference inhibition task
(Bush et al, 2008). The findings of upregulation of fronto-
striatal brain activation during interference inhibition in
ADHD boys in this study, however, are not in line with a
recent study of Peterson et al (2009), who found that MPH
had no effect on fronto-striatal activation during a Stroop
interference inhibition task, but enhanced activation in the
control condition of the task in the ventral anterior
cingulate and posterior cingulate, which was interpreted
as suppression of default-mode activity.
Also, in this study, we did not observe a normalization effect
of MPH on the dysfunction in medial frontal activation. Like
in this study, the SMA and anterior cingulate have previously
been found to be underactivated in ADHD patients during
interference inhibition tasks (Bush et al, 1999; Rubia et al,
2011). Previous studies, however, unlike this one, found a
modulation of either chronic (Bush et al, 2008) or single doses
of MPH (Vaidya et al, 1998) on this structure during motor
and interference inhibition, or on the control condition of the
task (Peterson et al, 2009). Differences in findings may be due
to the differences in task design or differences in medication
history, as patients were not medication naı ¨ve in these
previous studies.
We observed, however, normalization in a more ventro-
medial frontal location. Upregulation and normalization of
abnormal activation in this region has been observed in the
same patient group during a time discrimination task
(Rubia et al, 2009a). Ventromedial frontal cortex is thought
to be important for holding information in representational
memory (Schoenbaum et al, 2006) and has been associated
with selective attention and decision making (Christakou
et al, 2009b).
Posterior thalamic underactivation clusters in patients
relative to controls under placebo were also upregulated and
normalized with MPH. Posterior thalamic brain regions
have been associated both with inhibitory control (Aron
and Poldrack, 2006; Li et al, 2008), as well as attention to
salient stimuli such as oddball, novel, or incongruent targets
(Rubia et al, 2007c, 2009b,c; Stevens et al, 2007; Tamm et al,
2006). The significant normalization effects in inferior and
ventromedial frontal, striatal, and thalamic brain regions
therefore suggest that MPH appears to normalize activation
of all parts of a fronto-striato-thalamic cognitive control
network (Rubia et al, 2007c). Furthermore, this network
cluster was significantly associated with symptom severity
in ADHD patients. This suggests that MPH had a normal-
ization effect on brain deficits that are associated with
symptom severity, which may be the mechanism of action
that underlies behavioral improvement.
The inferior frontal underactivation cluster that was
normalized with the single MPH dose in patients, further-
more, reached into inferior parietal lobe in more superior
slices. To our knowledge, normalization of inferior parietal
activation with MPH has only recently been observed
in ADHD patients, in the context of sustained attention
(Rubia et al, 2009b) and another interference inhibition task
(Bush et al, 2008).
MPH prevents the reuptake of catecholamines from the
synaptic cleft by blocking DAT and norepinephrine
transporter (NET) (Volkow et al, 1995, 1997). In vitro
studies in animals show that MPH has high affinity for the
DAT, lower affinity for the NET, and minimum affinity for
the serotonin transporter (Bymaster et al, 2002; Gatley et al,
1996). In human kidney cells, MPH has shown to have
greater affinity for NET than DAT (Eshleman et al, 1999).
Positron emission tomography (PET) studies show that
MPH in healthy adults blocks 60–70% of striatal DAT in a
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extracellular DA in the striatum (Schiffer et al, 2006;
Volkow et al, 1997, 2002a,b, 2007a), as well as in frontal,
thalamic, and temporal brain regions (Montgomery et al,
2007). The upregulating effects on the caudate activation
were therefore likely mediated by effects on the dopami-
nergic system. In frontal regions, however, studies in rats
and mice have shown that MPH upregulates noradrenaline
to the same or greater extent than DA (Balcioglu et al, 2009;
Berridge et al, 2006). This is thought to be mediated by
reuptake inhibition of NET, as NET in frontal regions clear
up both DA and noradrenaline, given that there are few
DATs in these areas (Moron et al, 2002; Arnsten and
Dudley, 2005; Arnsten, 2006b; Berridge et al, 2006; Bymaster
et al, 2002; Staller and Faraone, 2007). The effects of MPH
on the inferior prefrontal activation could therefore have
been associated with both DA and noradrenaline upregula-
tion effects (Arnsten, 2006a). Likewise, the effect on
thalamic upregulation may have been mediated by blockage
of NETs, as these are densely distributed in the thalamus
(Hannestad et al, 2010). Furthermore, a recent PET study
showed that MPH at clinically relevant doses significantly
occupies 70–80% of NETs in NET-rich regions, including
cortical and thalamic areas, which is larger than the
percentage of blockage that has previously been observed
on DAT occupancy (Volkow et al, 1998). As opposed to the
significantly high blockage of DAT in striatal regions,
however, MPH had little effect on NET in the basal ganglia
(Hannestad et al, 2010). The upregulating effects
on frontal and thalamic activation, therefore, may have
been mediated by enhanced DA and noradrenaline neuro-
transmission caused by NET blockage, whereas basal
ganglia upregulation effects were more likely caused by
DAT-mediated effects on DA neurotransmission.
Patients compared with controls showed no performance
deficits. Evidence for performance deficits in tasks of
interference inhibition is controversial in the ADHD
literature (Mullane et al, 2009; Rubia et al, 2007a; van
Mourik et al, 2005). The negative findings may also be due
to the relatively low statistical power for neuropsychological
data and the use of an older adolescent age group compared
with the childhood age groups previously shown to have
performance deficits. The finding of no significant effects of
the clinical dose of MPH on performance on the Simon task
is in line with previous negative findings of an effect of
MPH in the related Stroop interference inhibition task
(Solanto et al, 2009). The findings of brain dysfunctions in
patients relative to controls and their upregulation and
normalization in boys with ADHD under the clinical dose of
MPH despite no observable performance changes show that
brain activation is more sensitive than performance to
detect both abnormalities and pharmacological effects. We
have previously shown that adolescents with ADHD show
marked brain dysfunctions despite no task impairment in
this and similar inhibition tasks (Rubia et al, 1999, 2005,
2009c) and brain activation has consistently been shown to
be more sensitive than behavior to show pharmacological
effects of MPH in ADHD patients (Bush et al, 2008; Konrad
et al, 2006; Peterson et al, 2009; Rubia et al, 2009ab; Shafritz
et al, 2004).
A limitation of the study is the relatively small sample
size. Minimum numbers of 15–20 participants have been
suggested for fMRI studies (Thirion et al, 2007). Repeated
measures designs, however, are statistically more powerful
than independent data sets, which makes the within-subject
ANOVA more robust. It cannot be excluded, however, that
with larger sample sizes upregulation or normalization
effects of MPH could be found for other brain regions. The
findings of region-specific normalization effects of MPH on
the activation in inferior frontal lobes and the basal ganglia,
therefore, need to be considered with caution until
replicated in larger datasets.
Another limitation of the study is that patients were tested
twice, whereas controls were only scanned once, for ethical
and financial reasons. Practice effects, however, were
overcome by the counterbalanced design.
Also, this experimental study investigated the effects of
one single clinical dose of MPH on brain activation in
medication-nı ¨ive boys with ADHD. Effects of a single acute
dose of MPH are not comparable to long-term MPH
treatment effects, where medication is typically titrated
and given over longer periods of time. Studies of acute
dosage only provide a unique probe of brief changes in
catecholamine modulation that can provide insights into
the effects of these brief changes on underlying brain
function. The findings of this study can therefore not be
transferred to elucidate underlying mechanisms of long-
term clinical treatment and are hence limited in their
applicability to clinical reality.
Furthermore, only male youth were included in the study
to increase sample homogeneity. ADHD is more prevalent
in boys (Merikangas et al, 2010) and gender differences
exist in clinical manifestation, cognitive deficits, and brain
dysfunctions (Gershon, 2002; Mahone and Wodka, 2008;
Valera et al, 2010). The findings may therefore not
generalize to the female youth population.
The task design did not include an absolute rest
condition, so that the active task condition (Simon
condition) was contrasted with lower-level baseline condi-
tions (ie, oddball; congruent trials). We found that the
activation differences were due to stronger activation in
controls relative to ADHD patients during the active task
(incongruent trials) relative to the lower-level baseline
conditions. The contrast of the active task condition with an
absolute baseline, such as a rest condition, could have
provided additional information that might have further
clarified the interaction findings. ADHD children, however,
are known to differ from controls in their brain activation
during the resting state (Konrad and Eickhoff, 2010) and a
resting condition may therefore not necessarily be more
disambiguating than a lower-level baseline condition.
In conclusion, to our knowledge, this is the first study to
show that a single clinical dose of MPH in medication-naı ¨ve
youth with ADHD has a region-specific effect of signifi-
cantly normalizing symptom-associated fronto-striatal un-
derfunctioning during interference inhibition.
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